MANE (MANE) Competitors

$114.58 +9.32 (+8.86%)

Closing price 03:59 PM Eastern

Extended Trading

$114.84 +0.25 (+0.22%)

As of 04:43 PM Eastern

MANE vs. PRAX, AXSM, ABVX, PCVX, and NUVL

Should you be buying MANE stock or one of its competitors? The main competitors of MANE include Praxis Precision Medicines (PRAX), Axsome Therapeutics (AXSM), Abivax (ABVX), Vaxcyte (PCVX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

How does MANE compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and MANE (NYSE:MANE) are both mid-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

: Praxis Precision Medicines presently has a consensus target price of $590.78, indicating a potential upside of 77.25%. MANE has a consensus target price of $83.33, indicating a potential downside of 27.27%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, equities analysts plainly believe Praxis Precision Medicines is more favorable than MANE.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)

12 Buy rating(s)

5 Strong Buy rating(s)
3.00
MANE
0 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.80
: MANE's return on equity of 0.00% beat Praxis Precision Medicines' return on equity.
Company Net Margins Return on Equity Return on Assets
Praxis Precision Medicines N/A -58.74% -53.54%
MANE N/A N/A N/A
: In the previous week, Praxis Precision Medicines had 3 more articles in the media than MANE. MarketBeat recorded 7 mentions for Praxis Precision Medicines and 4 mentions for MANE. Praxis Precision Medicines' average media sentiment score of 1.10 beat MANE's score of 0.92 indicating that Praxis Precision Medicines is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Praxis Precision Medicines
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MANE
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Praxis Precision Medicines N/A N/A -$303.27M -$13.46 N/A
MANE N/A N/A N/A N/A N/A
: 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.00
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-58.74%	-53.54%
MANE	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MANE	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.46	N/A
MANE	N/A	N/A	N/A	N/A	N/A

Summary

Praxis Precision Medicines beats MANE on 8 of the 10 factors compared between the two stocks.

How does MANE compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and MANE (NYSE:MANE) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

: In the previous week, Axsome Therapeutics had 40 more articles in the media than MANE. MarketBeat recorded 44 mentions for Axsome Therapeutics and 4 mentions for MANE. MANE's average media sentiment score of 0.92 beat Axsome Therapeutics' score of 0.38 indicating that MANE is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
13 Very Positive mention(s)
11 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
MANE
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 81.5% of Axsome Therapeutics shares are owned by institutional investors. 22.3% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: MANE has lower revenue, but higher earnings than Axsome Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axsome Therapeutics $638.50M 17.97 -$183.17M -$3.69 N/A
MANE N/A N/A N/A N/A N/A
: Axsome Therapeutics currently has a consensus target price of $251.89, indicating a potential upside of 12.93%. MANE has a consensus target price of $83.33, indicating a potential downside of 27.27%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than MANE.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
1 Sell rating(s)
1 Hold rating(s)

18 Buy rating(s)

1 Strong Buy rating(s)
2.90
MANE
0 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.80
: MANE has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -28.69%. MANE's return on equity of 0.00% beat Axsome Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics -28.69% -232.61% -25.84%
MANE N/A N/A N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	13 Very Positive mention(s)	11 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
MANE	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.97	-$183.17M	-$3.69	N/A
MANE	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-28.69%	-232.61%	-25.84%
MANE	N/A	N/A	N/A

Summary

Axsome Therapeutics beats MANE on 8 of the 12 factors compared between the two stocks.

How does MANE compare to Abivax?

Abivax (NASDAQ:ABVX) and MANE (NYSE:MANE) are both mid-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

: MANE's return on equity of 0.00% beat Abivax's return on equity.
Company Net Margins Return on Equity Return on Assets
Abivax N/A -146.43% -88.69%
MANE N/A N/A N/A
: In the previous week, Abivax had 3 more articles in the media than MANE. MarketBeat recorded 7 mentions for Abivax and 4 mentions for MANE. Abivax's average media sentiment score of 1.45 beat MANE's score of 0.92 indicating that Abivax is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abivax
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MANE
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abivax N/A N/A -$380.27M -$5.37 N/A
MANE N/A N/A N/A N/A N/A
: 47.9% of Abivax shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Abivax currently has a consensus price target of $137.15, suggesting a potential upside of 10.80%. MANE has a consensus price target of $83.33, suggesting a potential downside of 27.27%. Given Abivax's stronger consensus rating and higher probable upside, research analysts clearly believe Abivax is more favorable than MANE.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abivax
1 Sell rating(s)
0 Hold rating(s)

13 Buy rating(s)

1 Strong Buy rating(s)
2.93
MANE
0 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.80

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-146.43%	-88.69%
MANE	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MANE	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A
MANE	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Abivax beats MANE on 7 of the 9 factors compared between the two stocks.

How does MANE compare to Vaxcyte?

MANE (NYSE:MANE) and Vaxcyte (NASDAQ:PCVX) are both mid-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MANE N/A N/A N/A N/A N/A
Vaxcyte N/A N/A -$766.63M -$5.62 N/A
: 96.8% of Vaxcyte shares are held by institutional investors. 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: MANE's return on equity of 0.00% beat Vaxcyte's return on equity.
Company Net Margins Return on Equity Return on Assets
MANE N/A N/A N/A
Vaxcyte N/A -25.88% -23.85%
: In the previous week, Vaxcyte had 5 more articles in the media than MANE. MarketBeat recorded 9 mentions for Vaxcyte and 4 mentions for MANE. Vaxcyte's average media sentiment score of 0.94 beat MANE's score of 0.92 indicating that Vaxcyte is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MANE
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vaxcyte
6 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: MANE currently has a consensus target price of $83.33, suggesting a potential downside of 27.27%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 54.69%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than MANE.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MANE
0 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.80
Vaxcyte
1 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.63

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MANE	N/A	N/A	N/A	N/A	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$5.62	N/A

Company	Net Margins	Return on Equity	Return on Assets
MANE	N/A	N/A	N/A
Vaxcyte	N/A	-25.88%	-23.85%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MANE	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Vaxcyte beats MANE on 6 of the 9 factors compared between the two stocks.

How does MANE compare to Nuvalent?

MANE (NYSE:MANE) and Nuvalent (NASDAQ:NUVL) are both mid-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MANE N/A N/A N/A N/A N/A
Nuvalent N/A N/A -$425.38M -$5.85 N/A
: 97.3% of Nuvalent shares are held by institutional investors. 10.2% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: MANE's return on equity of 0.00% beat Nuvalent's return on equity.
Company Net Margins Return on Equity Return on Assets
MANE N/A N/A N/A
Nuvalent N/A -39.29% -35.01%
: In the previous week, Nuvalent had 6 more articles in the media than MANE. MarketBeat recorded 10 mentions for Nuvalent and 4 mentions for MANE. MANE's average media sentiment score of 0.92 beat Nuvalent's score of 0.56 indicating that MANE is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MANE
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nuvalent
5 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: MANE currently has a consensus target price of $83.33, suggesting a potential downside of 27.27%. Nuvalent has a consensus target price of $137.25, suggesting a potential upside of 35.26%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts plainly believe Nuvalent is more favorable than MANE.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MANE
0 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.80
Nuvalent
1 Sell rating(s)

0 Hold rating(s)

16 Buy rating(s)

0 Strong Buy rating(s)
2.88

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MANE	N/A	N/A	N/A	N/A	N/A
Nuvalent	N/A	N/A	-$425.38M	-$5.85	N/A

Company	Net Margins	Return on Equity	Return on Assets
MANE	N/A	N/A	N/A
Nuvalent	N/A	-39.29%	-35.01%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MANE	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Nuvalent beats MANE on 6 of the 9 factors compared between the two stocks.

Get MANE News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MANE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MANE vs. The Competition

Export

Metric	MANE	Pharmaceutical Preparations Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$4.28B	$892.30M	$4.21B	$22.95B
Dividend Yield	N/A	4.84%	5.61%	4.03%
P/E Ratio	N/A	1.72	23.40	28.57
Price / Sales	N/A	120.12	188.22	23.57
Price / Cash	N/A	20.07	52.82	19.03
Price / Book	N/A	7.60	38.44	4.68
Net Income	N/A	-$4.80M	$114.66M	$1.07B
7 Day Performance	10.90%	0.09%	1.34%	0.90%
1 Month Performance	79.16%	5.64%	5.68%	6.56%
1 Year Performance	N/A	30.92%	18.76%	31.66%

MANE Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MANE MANE	N/A	$114.58 +8.9%	$83.33 -27.3%	N/A	$4.28B	N/A	N/A	19	High Trading Volume
PRAX Praxis Precision Medicines	3.1948 of 5 stars	$344.82 +4.6%	$590.78 +71.3%	N/A	$9.60B	$8.55M	N/A	110
AXSM Axsome Therapeutics	3.1782 of 5 stars	$185.96 +1.8%	$218.06 +17.3%	N/A	$9.51B	$638.50M	N/A	380	Trending News Earnings Report Analyst Forecast
ABVX Abivax	3.1823 of 5 stars	$114.56 +1.4%	$137.15 +19.7%	N/A	$9.08B	N/A	N/A	61	Positive News Gap Up
PCVX Vaxcyte	2.1871 of 5 stars	$59.49 -2.1%	$86.00 +44.6%	N/A	$8.59B	N/A	N/A	160	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MANE) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MANE (MANE) Competitors

MANE vs. PRAX, AXSM, ABVX, PCVX, and NUVL

How does MANE compare to Praxis Precision Medicines?

Summary

How does MANE compare to Axsome Therapeutics?

Summary

How does MANE compare to Abivax?

Summary

How does MANE compare to Vaxcyte?

Summary

How does MANE compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

MANE Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MANE (MANE) Competitors

MANE vs. PRAX, AXSM, ABVX, PCVX, and NUVL

How does MANE compare to Praxis Precision Medicines?

Summary

How does MANE compare to Axsome Therapeutics?

Summary

How does MANE compare to Abivax?

Summary

How does MANE compare to Vaxcyte?

Summary

How does MANE compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

MANE Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools